Keyphrases
Clinical Trials
100%
Multiple Myeloma
100%
Systematic Literature Review
100%
Patient-reported Outcomes
100%
Patient-reported Outcome Instruments
66%
Patients with Hematological Malignancies
44%
Randomized Controlled Trial
44%
Trial Registries
33%
Patient-Reported Outcomes Measurement Information System (PROMIS)
22%
Inappropriate Use
22%
Multiple Myeloma Patients
22%
Cancer Patients
22%
Clinical Outcomes
11%
Hematology
11%
Stepwise Approach
11%
Adult Patients
11%
Myeloma
11%
Psychosocial Behavior
11%
Design Characteristics
11%
Functional Symptoms
11%
EORTC QLQ-C30
11%
Hematological Cancer
11%
Underutilization
11%
Functional Behavior
11%
Risk-benefit Ratio
11%
Specific Questionnaire
11%
Predefined Templates
11%
Drug Combination
11%
MEDLINE
11%
Underreported
11%
EQ-5D
11%
Treatment-related Adverse Events
11%
Physical Behavior
11%
EORTC
11%
Medicine and Dentistry
Clinical Trial
100%
Patient-Reported Outcome
100%
Systematic Review
100%
Multiple Myeloma
100%
Randomized Controlled Trial
25%
Hematologic Malignancy
25%
Hematological Cancer
6%
Myeloma
6%
Adverse Event
6%
Combination Drug
6%
Hematology
6%
Malignant Neoplasm
6%
DNA Template
6%
Functional Behavior
6%
Outcome Assessment
6%
Risk-Benefit Ratio
6%
Nursing and Health Professions
Patient-Reported Outcome
100%
Systematic Review
100%
Multiple Myeloma
100%
Hematologic Malignancy
25%
Practice Guideline
18%
Malignant Neoplasm
12%
Outcome Assessment
6%
Adverse Event
6%
Myeloma
6%
Combination Drug
6%
Clinical Outcome
6%
Pharmacology, Toxicology and Pharmaceutical Science
Multiple Myeloma
100%
Clinical Trial
100%
Randomized Controlled Trial
36%
Hematologic Malignancy
36%
Malignant Neoplasm
18%
Combination Drug
9%
Adverse Event
9%
Myeloma
9%
Biochemistry, Genetics and Molecular Biology
Randomized Controlled Trial
100%
Clinical Trial
100%
DNA Template
25%
Functional Behavior
25%